Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A thousand new regulators

Executive Summary

FDA will add 1,163 new employees to its staff by the end of the fiscal year, according to the agency. One thousand and five already are on board and 158 are due to report by Sept. 28. Another 160 candidates have accepted offers but are still undergoing clearance and related security processes, FDA says. The new hires, the result of a staffing initiative launched in the spring, will increase agency personnel to authorized levels (1"The Pink Sheet," May 5, 2008, p. 7). More than 850 of the new staff are in scientific or medical professions

You may also be interested in...

CDER, ORA To Be Major Beneficiaries Of Speedier FDA Hiring Process

As Congress debates increased funding and other steps to improve FDA oversight of imported drugs, the agency plans to hire 1,317 people in the next six months to bring staff numbers up to their full authorized levels

Ulta Beauty Leadership Offers 2023 Holiday Outlook, AI Update In Q3 Earnings Call

The US’ biggest beauty retailer is targeting fiscal 2023 net sales between $11.1bn and $11.15bn, with comparable sales growth of 5% to 5.5%, and is optimistic about 2024 and longer-term strategies. CEO David Kimbell addressed analyst questions on the 2023 holiday season, AI and other points of interest during the firm’s third-quarter earnings call.

Pharmative Sitting Out Trendy Spin-Off Dance

"Otsuka is very, very committed to nutraceuticals generally, and supplements specifically,” says Pharmavite CEO Jeff Boutelle.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts